Telix Pharmaceuticals Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TLX in the last 7 days.
No SEC Form 4 filings for $TLX in the last 30 days.
See all $TLX insider activity →Analysts reduced Telix Pharmaceuticals' average price target from $18.12 to $17.95, with a range of $13.18 to $22.08. This implies a 61% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 14 analysts.
Wedbush maintained an Outperform rating and $22 price target for Telix Pharmaceuticals, implying a 51.5% upside from its Oct 21 close. The company reported a 19% YoY revenue increase to $245M in Q3 2026 and reaffirmed FY26 revenue guidance exceeding $1B. Strategic partnerships and pipeline expansion were also highlighted.
Telix Pharmaceuticals reported Q3 2026 revenue of $245M, up 19% YoY, driven by strong demand for its PSMA products. Precision Medicine revenue grew 30% to $201M. The FDA approved Pixclara for glioma imaging, and the company completed BiPASS study enrollment. Telix also announced a merger with ITM, expecting FY 2026 revenue to exceed $1B.
Recent TLX coverage spans financial news, mergers & acquisitions and regulation.
Target cut suggests modest downside risk but still indicates ~61% upside from current price.
Analyst upgrade and higher price target may attract buying interest.
Merger creates a vertically integrated radiopharma platform, likely boosting Telix valuation.
The partnership could lift Telix's pipeline prospects and drive near‑term stock upside.
First FDA‑cleared radiodiagnostic for glioma, expanding Telix's commercial addressable market.
AlphAI scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts reduced Telix Pharmaceuticals' average price target from $18.12 to $17.95, with a range of $13.18 to $22.08. This implies a 61% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 14 analysts.
1 min readWedbush maintained an Outperform rating and $22 price target for Telix Pharmaceuticals, implying a 51.5% upside from its Oct 21 close. The company reported a 19% YoY revenue increase to $245M in Q3 2026 and reaffirmed FY26 revenue guidance exceeding $1B. Strategic partnerships and pipeline expansion were also highlighted.
1 min readTelix Pharmaceuticals reported Q3 2026 revenue of $245M, up 19% YoY, driven by strong demand for its PSMA products. Precision Medicine revenue grew 30% to $201M. The FDA approved Pixclara for glioma imaging, and the company completed BiPASS study enrollment. Telix also announced a merger with ITM, expecting FY 2026 revenue to exceed $1B.
2 min readTelix Pharmaceuticals and Ekalia (a joint venture between IBA and Framatome) are collaborating to establish U.S. production of astatine-211 (211At), a rare radioisotope for cancer treatment. The partnership will use IBA's cyclotron technology and Telix's U.S. radiopharmacy infrastructure. Telix aims to advance its alpha therapy pipeline, including TLX102-Tx for glioblastoma, and support third-party research.
2 min readThe FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.
3 min readTelix announced US commercial availability of floretyrosine F 18, distributed by PharmaLogic, for differentiating glioma. Knight Therapeutics launched Tavalisse in Brazil for chronic immune thrombocytopenia, licensed from Rigel Pharmaceuticals.
1 min readProfound Medical Corp. (PROF) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound
2 min readProfound Medical (PROF) and Telix Pharmaceuticals (TLX) partnered to educate physicians on combining PSMA-PET imaging and MRI-guided TULSA-PRO treatment for prostate cancer. The agreement focuses on U.S. and international markets, with plans for medical meetings, webinars, and clinical case studies. Profound is also developing software to integrate PSMA-PET and MRI imaging.
2 min readTelix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is acquiring ITM Isotope Technologies Munich SE in a $1.65 billion deal, with up to $700 million in additional payments tied to milestones. The acquisition aims to expand Telix's isotope production and therapeutic pipeline.
1 min readTelix Pharmaceuticals announced the first U.S. patients have been dosed with Pixclara, its FDA-approved imaging drug for glioma (brain cancer). Pixclara is the only FDA-approved radiopharmaceutical for this indication. The drug is now commercially available in the U.S., supplied by PharmaLogic Holdings Corp.
2 min read
